Mechanisms proposed to address the lower expression of GLT-1 or mutations in GLT-1 may represent a novel strategy for the treatment of drug-resistant epilepsy; however, the underlying molecular cascade of responses remains largely unexplored. Here, SLC1A2 is linked to epilepsy.